Fundz
An acquisition means integration work is about to be scoped. Fundz scores the company against what you sell, and says why it matched.See it live →

GTBL acquires MicroBiopharm Japan for ¥21.5B

PRIVATESep 18, 2026about 2 hours ago

Acquiring Company

Gujarat Themis Biosyn Limited

Acquired Company

MicroBiopharm Japan Ltd

MumbaiJapanManufacturingBiotechnologyHealth CarePharmaceuticalManufacturingBiotechnology

Description

Gujarat Themis Biosyn Limited (GTBL) has completed the acquisition of MicroBiopharm Japan for ¥21.5 billion. This strategic move gives GTBL access to advanced technologies and established relationships within the global pharmaceuticals market. The acquisition aligns with GTBL's ambition to transform into a fully integrated global CDMO. With this deal, GTBL aims to enhance its competitiveness in the pharmaceutical landscape.

Company Information

Company

Gujarat Themis Biosyn Limited

Location

Mumbai, Maharashtra, India

About

Gujarat Themis Biosyn Limited is a leading biopharmaceutical company focused on fermentation-based intermediates and contract development manufacturing. The company is committed to advancing in biotechnology and pharmaceutical sciences. It aims to evolve into a technology-driven platform by acquiring complementary capabilities through strategic mergers and acquisitions.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Gujarat Themis Biosyn Limited makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Trusted by

OracleSnowflakeCloudflareLinkedInGoogleSalesforce
4.8/5 on G2· Since 2015
Predictive Intelligence
Strategic

ML-powered predictions for Gujarat Themis Biosyn Limited's next move

Learn about Strategic plan

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed

Frequently asked

Who acquired MicroBiopharm Japan Ltd?

MicroBiopharm Japan Ltd was acquired by Gujarat Themis Biosyn Limited, based in Mumbai. The deal was reported on September 18, 2026. Gujarat Themis Biosyn Limited is a leading biopharmaceutical company focused on fermentation-based intermediates and contract development manufacturing. Gujarat Themis Biosyn Limited is privately held and operates in Manufacturing.

When did Gujarat Themis Biosyn Limited acquire MicroBiopharm Japan Ltd?

Gujarat Themis Biosyn Limited's acquisition of MicroBiopharm Japan Ltd was reported on September 18, 2026. Gujarat Themis Biosyn Limited (GTBL) has completed the acquisition of MicroBiopharm Japan for ¥21.5 billion. This strategic move gives GTBL access to advanced technologies and established relationships within the global pharmaceuticals market. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does MicroBiopharm Japan Ltd do?

MicroBiopharm Japan Co., Ltd. (MBJ) is a well-established Japanese company with over sixty years of experience in fermentation and microbial-based R&D. It is privately held, operating in Manufacturing, and is based in Japan.

This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 285,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.